China broke ground on what developers describe as the first AI-powered production line for personalized tumor vaccines in Beijing. Likang Life Sciences said the facility will support lab work and scale manufacturing for LK101, which analyzes patient tumor DNA to identify tumor-specific mutations. The company claims AI-driven workflows could compress parts of the process to about a day. If realized at scale, the model would shift cancer vaccine production toward rapid personalization and could accelerate capacity for mutation-matched immunotherapies as China expands its cell- and gene-therapy infrastructure.